Clinical trials: Acquired Immune Deficiency Syndrome
Cytomegalovirus Infections, HIV Infections
A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection
To evaluate the clinical and laboratory toxicity of ganciclovir (GCV) and zidovudine (AZT) when given in combination. Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with…
- Trial name
- NCT00000995
- Testing
- Zidovudine, Ganciclovir
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv
Enhancing PrEP Outcomes Among Kenyan Adolescent Girls and Young Women With a Novel Pharmacy-based PrEP Delivery Platform
The investigators will conduct a cluster RCT in Kisumu, Kenya to determine the effect of nurse-navigators on PrEP initiation, persistence, and adherence among AGYW seeking contraception within a pharmacy-based PrEP delivery…
- Trial name
- NCT05467306
- Testing
- Nurse-Navigator Enhanced PrEP Support
- Where
- Kenya
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- University of Washington
HPV, Human Papilloma Virus
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
There are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer.
- Conditions
- HPV, Human Papilloma Virus, Human Immunodeficiency Virus
- Trial name
- NOVA-HIV (NCT05495906)
- Testing
- Nonavalent HPV vaccine
- Where
- 10 sites in Canada
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
HIV-1 Infection, AIDS
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
The objective of the OPTIMAL study is to demonstrate that the adjunction of Maraviroc to a combination of antiretroviral therapy in naive and late diagnosed HIV-1 infected patients counts may accelerate the kinetics of immune…
- Trial name
- OPTIMAL (NCT01348308)
- Testing
- Maraviroc (Celsentri)
- Where
- France
- Volunteers
- 407 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV/AIDS, Cocaine Use
Project SMART Automated Pillbox Study
The aim of this study is to examine the effect of mHealth tools on antiretroviral (ART) adherence and persistence among HIV-infected individuals with co-occurring cocaine use disorders (CUDs).
- Trial name
- SMART (NCT04418076)
- Testing
- Group A_No feedback, Group B_Automated feedback, Group C_Automated feedback + Clinician feedback
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Yale University
Healthy Volunteers
Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects
This will be an open-label, fixed-sequence, multiple dose crossover study in 14 healthy male and/or female subjects, to estimate the effect of steady state lersivirine on the steady state pharmacokinetics of abacavir/lamivudine.
- Trial name
- NCT01220232
- Testing
- Abacavir/Lamivudine, Lersivirine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)
To define the pharmacokinetic characteristics of Nystatin LF IV (intravenous) in human subjects with AIDS-related complex (ARC) after administration of a single IV dose at each of 4 dose levels.
- Trial name
- NCT00001998
- Testing
- Nystatin
- Where
- United States
- Sponsor
- Argus Pharmaceuticals
Hiv
Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program
The Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions.
- Trial name
- D2S (NCT05140421)
- Testing
- Data to Suppression (D2S), Usual practice
- Where
- 27 sites in United States
- Volunteers
- 1,494 people
- Sponsor
- City University of New York
Human Immunodeficiency Virus
Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
The two original objectives were to determine in HIV-infected children initiating antiretroviral therapy (ART): 1. Whether clinically driven monitoring (CDM) will have a similar outcome in terms of disease progression or death as…
- Trial name
- ARROW (NCT02028676)
- Testing
- Clinically Driven Monitoring (CDM), Laboratory plus Clinical Monitoring (LCM), Arm A: ABC+3TC+NNRTI
- Where
- 4 sites in Uganda, Zimbabwe
- Volunteers
- 1,206 people
- Sponsor
- Medical Research Council
HIV/AIDS
Swaziland HIV Incidence Measurement Survey 2
The second Swaziland HIV Incidence Measurement Survey (SHIMS 2, 2016), is a population based HIV Impact Assessment (PHIA) that will assess the prevalence of key human immunodeficiency virus (HIV)-related health indicators.
- Trial name
- SHIMS2 (NCT04117984)
- Where
- Eswatini
- Volunteers
- 15,429 people, healthy volunteers welcome
- Sponsor
- Columbia University
Human Immunodeficiency Virus; HIV
An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
The purpose of this study is to study the kinetics (study of the rate of change) of immune recovery quality and function in stored plasma blood samples of treatment-naive (not previously treated with antiretroviral drugs)…
- Trial name
- NCT01541085
- Testing
- Darunavir/Ritonavir (DRV/r), Efavirenz (EFV)
- Volunteers
- 33 people
- Sponsor
- Janssen-Cilag S.p.A.
HIV Infection
Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients
The objective of this study is to determine the pharmacokinetics of lopinavir, ritonavir, and atazanavir when lopinavir/ritonavir and atazanavir are used in combination.
- Trial name
- NCT00420355
- Testing
- atazanavir, lopinavir/ritonavir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Oklahoma
HIV Infections
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
The purpose of this study is to evaluate the safety and efficacy of a novel nucleoside sparing regimen containing atazanavir, ritonavir and efavirenz, using two different doses of atazanavir.
- Trial name
- NCT00135343
- Testing
- Atazanvir/ritonavir + efavirenz
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
HIV/AIDS
Multi-vitamins, HAART and HIV/AIDS in Uganda
The investigators are conducting a double-blind, placebo controlled,randomized trial of multivitamin supplements(containing B-vitamins, C, and E) to determine their efficacy in slowing disease progression, indicated by increased…
- Trial name
- NCT01228578
- Testing
- Multivitamin supplements B,C and E
- Where
- Uganda
- Volunteers
- 400 people
- Sponsor
- Harvard School of Public Health (HSPH)
HIV-infection/Aids, Coronavirus Infection
COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings
COHIVE is an observational cohort nested in four antiretroviral therapy research studies (ADVANCE - NCT03122262; D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 - NCT02777229).
- Trial name
- NCT04371835
- Where
- 15 sites in Argentina, Brazil and 8 more
- Volunteers
- 596 people
- Sponsor
- Kirby Institute
HIV 1 Infection
Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO).
Women are an underrepresented population in clinical studies on HIV and antiretroviral therapy. This study aims to help bridge this gap by providing real-world data on therapeutic management with B/F/TAF (Biktarvy) in an…
- Trial name
- BIKWO (NCT07859904)
- Testing
- Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
HIV Infections
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior…
- Trial name
- NCT00000838
- Testing
- Lamivudine, Stavudine, Zidovudine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 256 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Using CBPR to Reduce HIV Risk Among Immigrant Latino MSM
The intervention is based on social cognitive theory and theory of empowerment education and was developed using community-based participatory research (CBPR).
- Trial name
- HOLA (NCT03276338)
- Testing
- HOLA
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
HIV Infections
A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People
This phase I study is the first step to determine if Opal immunotherapy may have potential utility as a treatment for HIV. Although effective treatments for HIV infection exist, they are limited by the requirement for life-long…
- Trial name
- NCT01123915
- Testing
- Opal-HIV-Gag(c) Low Dose, Opal-HIV-Gag(c) Medium dose, Opal-HIV-Gag(c) High dose
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Medicines Development for Global Health
Sarcoma, Kaposi, HIV Infections
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha.
- Trial name
- NCT00000725
- Testing
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.